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Case RepoRt
Antibodies against Lutheran blood group antigens have been 
observed during first-time pregnancy. Samples from a woman of 
African descent were tested in our immunohematology laboratory 
on several occasions since 2001. Her samples were phenotyped 
as Lu(a+b−), and anti-Lub was suspected but not identified. She 
was asked to make autologous donations in preparation for her 
delivery, which she did. In 2010, two antibodies were identified: 
anti-Lea and -Lub. Six years later, a third investigation was 
requested. This time, an antibody directed at a high-prevalence 
Lutheran antigen was found in addition to the anti-Lea and -Lub 
previously observed. Her serum was compatible with three 
out of five Lu(a−b−) reagent red blood cells (RBCs). One of the 
incompatible Lu(a−b−) reagent RBCs was known to be In(Lu) 
(KLF1 mutation). The genetic background of the other reagent 
RBC was unknown. The LU cDNA sequence analysis revealed the 
presence of the c.230G>A (Lua), c.679C>T (LU:–16), and a silent 
polymorphism c.1227G>T. Anti-Lu16 was highly suspected. This 
would be the fifth case of LU:–16 with antibodies reported, all 
within women of African heritage with the Lu(a+b−) phenotype. 
Hemolytic disease of the fetus and newborn was not noted in 
these cases. Immunohematology 2017;33:110–113.
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Lutheran antigens (blood group system ISBT 006) 
are carried on type I integral membrane glycoproteins, 
members of the immunoglobulin super family. According to 
the International Society of Blood Transfusion (ISBT) Web 
site, this blood group system comprises 24 antigens.1 Two 
additional antigens were presented at the 2016 ISBT meeting 
in Dubai (LUAC and LUBI).2 Most Lutheran antigens are of 
high prevalence. Only four allelic and polymorphic pairs have 
been found so far: Lua/Lub, Aua/Aub, Lu6/Lu9, and Lu8/Lu14.3
The gene encoding the Lutheran antigens, LU, spans 
12.5 kb, contains 15 exons (14 of which are involved in 
the coding part) for the shortest transcript, and is located 
on chromosome 19q13.32 (Unigene NP_005572.2). The 
molecular basis involved in expression or absence of the 
Lutheran antigens has been elucidated over the years.4–10
In 1980, Sabo et al.11 presented three cases of Lu(a+b−) 
women of African descent in whom anti-Lub was found 
along with another antibody against a high-prevalence 
antigen believed to be in the Lutheran system. This antibody 
was similar in all three women as well as when tested with 
Lu(a−b−) cells of the dominant and recessive types. However, 
the antibody produced by these three women was different 
from those previously identified. Anti-Lu16 was proposed.
A fourth example was published more recently by 
Denomme et al.12 in 2010. It was the case of a young woman of 
African heritage in her first pregnancy. Her RBCs phenotyped 
as Lu(a+b−). Anti-Lub was found as well as a second antibody 
against a high-prevalence Lutheran antigen. This patient was 
found to be homozygous for the c.679C>T (p.Arg227Cys) 
polymorphism in exon 6 encoding the LU:–16 phenotype. The 
neonatal outcome of this pregnancy was not associated with 
any incident.
We here report a fifth LU:–16 case similar to the first four 
already described.
Case Report
Samples from a woman of African descent born in 
1978 were referred for antibody identification during three 
pregnancies starting in 2001. A fourth sample followed in 2013 
and a fifth in 2016. The patient had a total of six pregnancies 
in 1999, 2001, 2003, 2010, 2013, and 2016. Her phenotype 
was the following: group A2B; D+ C− E+ c+ e+ Cw−; M+ N+ 
S− s+; Le(a−b−); K− Kp(a–); Fy(a−b−); Jk(a+b−); Lu(a+b−). 
Reagents were from Ortho Clinical Diagnostics (Raritan, NJ), 
Dominion Biologicals (Dartmouth, Nova Scotia, Canada), Bio-
Rad (Montreal, Quebec, Canada), and Lorne (Lower Early, 
UK).
First Investigation, 2001 (Second Pregnancy)
Two samples were received in 2001: one in March and one 
in April. The patient was 22 weeks pregnant at the time the 
first sample was received.  The hospital results showed a weak 
reaction with Lu(a+b+) reagent RBCs tested in gel at 37°C. 
The results obtained by an immunohematology reference 
laboratory (IRL) showed no reactivity with three different 
Lu(a+b−) reagent RBCs in a polyethylene glycol indirect 
antiglobulin test (PEG-IAT; Immucor, Norcross, GA) and in 
gel at 37°C (MTS, Ortho Clinical Diagnostics) and showed 
IMMUNOHEMATOLOGY, Volume 33, Number 3, 2017 111
A LU:–16 individual with antibodies
positive reactivity with all Lu(a−b+) panel cells in PEG-IAT. 
All reactions were negative at 4°C; auto control was negative. 
Titers performed in PEG with Lu(a+b+) reagent and with fresh 
RBCs were 1 and 128, respectively. 
The report sent to the hospital mentioned high-titer, low-
avidity (HTLA) reactivity, and anti-Lub could not be ruled 
out. Because the patient had a rare blood phenotype, she was 
encouraged to make autologous donations in preparation for 
her delivery. These donations were made in July.
Second Investigation, 2010 (Fourth Pregnancy)
Hospital results on samples submitted in 2010 during 
her fourth pregnancy showed weak to 1+ panagglutination 
with two commercial panels (Immucor). The auto control was 
negative. The IRL tested cells in different media: gel–low-
ionic-strength saline (LISS) (Diagast, Loos, France), gel-ficin 
(Sigma-Aldrich, Oakville, Ontario, Canada), gel-dithiothreitol 
(DTT) (Sigma-Aldrich), and gel-trypsin, (Sigma-Aldrich). 
Reactions varied from weak to 2½+, except in gel-trypsin 
where reactions were weaker. Auto controls were negative. No 
reactions were seen with nine Lu(a+b−) reagent RBCs, and 
a 2½+ reaction was observed with three Le(a+b−) Lu(a+b−) 
reagent RBCs.
In-house polymerase chain reaction–sequence specific 
primer (PCR-SSP) analyses were performed to confirm the 
Duffy phenotype (c.125G>A for FY*01/FY*02 and c.−67T>C 
for FY*01N.01). A polymorphism was found at the GATA-1 
binding site at position –67 within the FY gene causing the 
Fy(a−b−) phenotype.
The report sent to the hospital mentioned two antibodies: 
anti-Lea and -Lub. The “HTLA” reactivity could not be found.
Third Investigation, 2016 (Sixth Pregnancy)
Two samples were sent to the IRL in 2016 during the 
patient’s sixth pregnancy: one in March and one in June 
(Table 1). The March sample showed 1½+ to 2+ reactivity 
with five Lu(a+b−) reagent RBCs in gel-LISS and gel-papain 
(Immucor), 2+ to 2½+ reactivity with two Lu(a+b−) reagent 
RBCs in gel-DTT, and no reactivity with two Lu(a+b−) reagent 
RBCs in gel-trypsin. The auto control was negative in all of the 
media tested. No reaction was observed after alloadsorption 
onto Lu(a−b+) RBCs. 
Testing with cord blood samples showed no reactivity 
with one of the cells; adult cells were reactive 1+ in saline at 
22°C. One cord blood sample was negative in gel-LISS, and 
one showed very weak reactivity. 
Testing with two Lu(a−b−) cell samples showed no 
reactivity with one sample in gel-LISS and gel-papain. The 
second cell sample was very weakly reactive in gel-LISS and 
2+ in gel-papain (Table 1).
Serum adsorbed with rabbit erythrocyte stroma (RESt, 
Immucor) was tested with two group A, Lu(a+b−) cell samples 
in gel-papain with negative reactions and with two group O 
Lu(a+b−) cell samples in gel-papain in which one of the two 
Table 1. Third serology study summary done in 2016
Red blood cells Reactivity
Phenotype Source/Donor # Method March sample June sample
15-cell in-house 
panel
Gel LISS 1½+ to 2½+ 2½+ to 3+
Gel papain w+ to 2½+ 2½+ to 3+
Group O, 
Lu(a+b–)
C5147 Gel LISS 1½+ to 2+ NT
Gel papain 1½+ to 2+ NT
04 10 486280 Gel LISS 1½+ to 2+ NT
Gel papain 1½+ to 2+ NT
DTT 2+ to 2½+ NT
Gel trypsin 0 NT
04 10 492148 Gel LISS 1½+ to 2+ NT
Gel papain 1½+ to 2+ NT
DTT 2+ to 2½+ NT
Gel trypsin 0 NT
Group A, 
Lu(a+b–)
03 11 650893 Gel LISS 1½+ 3+
Gel papain 1½+ 3+
04 13 792604 Gel LISS 1½+ NT
Gel papain 1½+ NT
03 11 870278 Gel LISS NT 3+
Gel papain NT 3+
Group O, 
Lu(a–b–)
03 10 297468* Gel LISS vw+ NT
Gel papain 2+ NT
09 012795 Gel LISS 0 NT
Gel papain 0 NT
06 12 000021 Gel LISS NT 0
Gel papain NT 0
06 12 000189 Gel LISS NT 0
Gel papain NT 0
06 12 001623 Gel LISS NT 1+
Gel papain NT 1+
Alloadsorptions 
onto three  
Lu(a–b+) cells  
(D1, D2, D3)
Gel LISS 0 NT
Gel papain 0 NT
*03 10 297468: In(Lu) phenotype. This individual was found heterozygous 
for KLF1 c.874A>T (KLF1*BGM04). Unknown genetic background for the 
other Lu(a−b−) cells tested.
LISS = low-ionic-strength saline; w = weak; NT = not tested;  
DDT = dithiothreitol; vw = very weak.
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samples gave a negative reaction. RESt is known to adsorb 
cold-reactive autoagglutinins, anti-B, -P, and some monoclonal 
IgM alloantibodies.13 The initial report sent to the hospital 
mentioned the presence of anti-Lub and a cold agglutinin.
In-house PCR–restriction fragment length polymorphism 
analyses predicted the following Knops phenotype: Kn(a+b−), 
McC(a+b+), Sl1/Sl2, Yka+. LU and KFL1 mRNA were sequenced. 
The LU sequence showed three homozygous polymorphisms: 
c.230G>A (p.Arg77His), c.679C>T (p.Arg227Cys), and 
c.1227G>T (p.Leu409Leu), encoding a LU:1,–2,–16 phenotype. 
The KLF1 sequence showed two novel heterozygous 
polymorphisms: c.544T>C (p.Phe182Leu) and c.894G>T 
(p.Ala298Ala).
The second sample, received a few months later, showed 
stronger reactions (2½+ to 3+) in gel-LISS and gel-papain even 
with Lu(a+b−) reagent RBCs. Auto controls were negative. No 
reactions were seen with two of three Lu(a−b−) reagent RBCs.
A new report was sent to the hospital stating a known 
anti-Lub and a suspected anti-Lu16.
Discussion
The five LU:–16 cases reported until now have been women 
of African heritage with a Lu(a+b−) phenotype. According 
to Reid et al.,3 these individuals should be transfused with 
Lu(a−b−) of either dominant [KLF1 heterozygous mutation or 
In(Lu)] or recessive types (true Lunull). Our results, however, 
showed an incompatibility with two of the five Lu(a−b−) 
reagent RBC samples tested. Blood should be carefully selected 
before transfusion.
The Erythrogene database14 shows the highest LU*01 
allele frequency in those of African descent at 0.76 percent 
and a frequency of 0.14 percent in Caucasians, for a mean 
allele frequency of 0.22 percent. It also indicates the presence 
of LU*01.–16 allele in 0.61 percent of individuals of African 
origin. The KLF1 polymorphism c.544T>C (p.Phe182Leu) 
found in this study was listed in the Erythrogene database in 
association with other polymorphisms different from the one 
found in this case [c.894G>T (p.Ala298Ala)]. It is difficult to 
conclude whether this patient’s polymorphism would have an 
effect on the expression of the Lutheran or other blood group 
antigens, since her Lua typing was normal.
Most Lu(a−b−) cells tested were from the Serum, 
Cells, and Rare Fluids Exchange (SCARF) without genetic 
background details, except one known to have a KLF1 
c.874A>T heterozygous polymorphism causing a dominant 
In(Lu) (p.Lys292Ter, KLF1*BGM04).15 In such a phenotype, 
Lutheran antigens are weakly expressed and could explain the 
reactions seen. These cells were not tested with other Lutheran 
antibodies, however.
This case was referred to us for antibody identification 
during three pregnancies. Several antibodies were found 
without any adverse effects on the neonates. 
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